Resistance in Hematologic Malignancies and Cancer
portes grátis
Resistance in Hematologic Malignancies and Cancer
Messingerova, Lucia; Breier, Albert
Elsevier Science Publishing Co Inc
11/2024
326
Dura
9780443217906
Pré-lançamento - envio 15 a 20 dias após a sua edição
Descrição não disponível.
1. Drug classification for treatment Hematological Malignancies
2. Reduce drug uptake in development of resistance
3. The Role of Enhanced Drug Efflux in Drug Resistance
4. MicroRNAs and other non-coding RNA species in diagnostics, prognostics and therapy response of blood cancers.
5. Switching between autophagy and apoptosis pro-survival and pro-death balance in leukemia cells
6. The role of UPR signaling pathways in cancer cell resistance to chemotherapy
7. Altered cell cycle regulation
8. Deregulation of drug metabolizing enzymes and transporters in cancer via the aryl hydrocarbon receptor
9. Immune system in resistance prediction
10. Mechanisms of resistance of antibody-drug conjugates - obstacles to overcome
11. Resistance to Chimeric Antigen Receptor T Cells (CAR-T)
2. Reduce drug uptake in development of resistance
3. The Role of Enhanced Drug Efflux in Drug Resistance
4. MicroRNAs and other non-coding RNA species in diagnostics, prognostics and therapy response of blood cancers.
5. Switching between autophagy and apoptosis pro-survival and pro-death balance in leukemia cells
6. The role of UPR signaling pathways in cancer cell resistance to chemotherapy
7. Altered cell cycle regulation
8. Deregulation of drug metabolizing enzymes and transporters in cancer via the aryl hydrocarbon receptor
9. Immune system in resistance prediction
10. Mechanisms of resistance of antibody-drug conjugates - obstacles to overcome
11. Resistance to Chimeric Antigen Receptor T Cells (CAR-T)
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
<p>Tumor microenvironment, hemo-oncology; hematology; drug resistance; mrRNA; autophagy; malignancies</p>
1. Drug classification for treatment Hematological Malignancies
2. Reduce drug uptake in development of resistance
3. The Role of Enhanced Drug Efflux in Drug Resistance
4. MicroRNAs and other non-coding RNA species in diagnostics, prognostics and therapy response of blood cancers.
5. Switching between autophagy and apoptosis pro-survival and pro-death balance in leukemia cells
6. The role of UPR signaling pathways in cancer cell resistance to chemotherapy
7. Altered cell cycle regulation
8. Deregulation of drug metabolizing enzymes and transporters in cancer via the aryl hydrocarbon receptor
9. Immune system in resistance prediction
10. Mechanisms of resistance of antibody-drug conjugates - obstacles to overcome
11. Resistance to Chimeric Antigen Receptor T Cells (CAR-T)
2. Reduce drug uptake in development of resistance
3. The Role of Enhanced Drug Efflux in Drug Resistance
4. MicroRNAs and other non-coding RNA species in diagnostics, prognostics and therapy response of blood cancers.
5. Switching between autophagy and apoptosis pro-survival and pro-death balance in leukemia cells
6. The role of UPR signaling pathways in cancer cell resistance to chemotherapy
7. Altered cell cycle regulation
8. Deregulation of drug metabolizing enzymes and transporters in cancer via the aryl hydrocarbon receptor
9. Immune system in resistance prediction
10. Mechanisms of resistance of antibody-drug conjugates - obstacles to overcome
11. Resistance to Chimeric Antigen Receptor T Cells (CAR-T)
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
